Study guide
12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock
Certified Specialist in Poison Information CSPI
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacology & Toxicology Principles
1.1 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination Alterations in Overdose 1.2 Toxicodynamics, Receptor Pharmacology, and Dose-Response Relationships 1.3 Cellular and Biochemical Mechanisms of Toxicity 1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions
2 Chapter 2: Poison Center Case Assessment Fundamentals
2.1 Exposure History: The Questions That Change Management 2.2 Toxicologic Calculations: Doses, Concentrations, and Conversions
3 Chapter 3: Analgesics, Opioids & Over-the-Counter Medications
3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols 3.2 Salicylates: Pathophysiology, Acid-Base Derangements, and Urinary Alkalinization 3.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Miscellaneous OTC Analgesics 3.4 Opioids, Opioid Toxidrome, and Naloxone Titration 3.5 Cough and Cold Products, Antihistamines, Muscle Relaxants, and Local Anesthetics
4 Chapter 4: Psychotropic & Neurologic Medications
4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy 4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome 4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity 4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants
5 Chapter 5: Cardiovascular Drugs & Substances of Abuse
5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy 5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab 5.3 Sympathomimetics, Cocaine, Amphetamines, Synthetic Cannabinoids, and Hallucinogens 5.4 Caffeine, Theophylline, and Over-the-Counter Stimulants 5.5 Cannabis, GHB, Nitrites, and Nicotine Products
6 Chapter 6: Endocrine, Antimicrobial & Miscellaneous Medications
6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone 6.2 Antimicrobials, Vitamins and Minerals, and Veterinary Products
7 Chapter 7: Household, Chemical & Inhalational Toxins
7.1 Caustic and Corrosive Ingestions: Acids vs. Alkalis, Tissue Necrosis, and Endoscopic Grading 7.2 Cleaning Products, Personal Care Products, and Household Chemicals 7.3 Hydrocarbons and Halogenated Solvents: Aspiration Risks and Myocardial Sensitization 7.4 Carbon Monoxide, Cyanide, Hydrogen Sulfide, and Inhalational Irritants
8 Chapter 8: Pesticides, Heavy Metals & Toxic Alcohols
8.1 Organophosphates, Carbamates, Pyrethroids, and Cholinesterase Antidotes 8.2 Rodenticides, Herbicides, Repellents, and Other Pesticides 8.3 Ethylene Glycol, Methanol, and Isopropanol: Metabolism, Osmolal Gaps, and Fomepizole 8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols
9 Chapter 9: Toxic Plants, Mushrooms & Foodborne Toxins
9.1 Toxic Plants: Cardiac Glycosides, Anticholinergics, Nicotinics, and Sodium Channel Activators 9.2 Oxalate, Irritant, Hallucinogenic, and Stimulant Plants 9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine 9.4 Scombroid, Ciguatera, Tetrodotoxin, Paralytic Shellfish, and Botulism 9.5 Bacterial Foodborne Illness and Food Poisoning Triage
10 Chapter 10: Envenomations & Bites
10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management 10.2 Elapid Snakebites (Coral Snakes): Neurotoxicity, Clinical Course, and Antivenin 10.3 Black Widow, Brown Recluse Spiders, and Bark Scorpion Stings 10.4 Hymenoptera Stings, Ticks, and Other Arthropods 10.5 Marine Envenomations: Jellyfish, Stingrays, Catfish, and Lionfish
11 Chapter 11: Clinical Assessment, Toxidromes & Triage
11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis 11.2 Severity Assessment, Exposure Urgency, and Poison Center Telephone Triage Flow 11.3 Home Observation vs. Emergency Department Referral Decision-Making 11.4 Diagnostic Toxicology: Acid-Base Analysis, Gaps, ECG Intervals, and Drug Testing
12 Chapter 12: Decontamination, Antidotes & Elimination
12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications 12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls 12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion 12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock
13 Chapter 13: Pediatric Poisoning & High-Risk Hazards
13.1 Pediatric "One-Pill-Can-Kill" Agents and Pediatric Toxic Dose Thresholds 13.2 Button Batteries, Rare-Earth Magnets, and Expandable Foreign Bodies 13.3 Developmental Ingestion Patterns, Liquid Detergent Pods, and Essential Oils
14 Chapter 14: Communication, NPDS Documentation & Prevention
14.1 Emergency Call Communication, Panicked Callers, and Healthcare Provider Consultations 14.2 National Poison Data System (NPDS) Coding Standards and Medical Outcome Categorization 14.3 Scheduled Follow-up Protocols, Medical Toxicologist Consultation Triggers, and Public Health Surveillance 14.4 Evidence-Based Poison Prevention, PPPA Regulations, and Community Outreach
12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock
Key Takeaways Explain This Topic AI
Toxic seizures are driven primarily by GABA antagonism, impaired GABA synthesis, or sodium channel blockade; intravenous benzodiazepines are the first-line therapeutic agents, whereas phenytoin is ineffective in toxic seizures and absolutely contraindicated in sodium-channel blocker poisoning due to additive cardiotoxicity.
Toxin-specific seizure etiologies mandate specific antidotal therapy alongside benzodiazepines: pyridoxine for isoniazid and Gyromitra mushroom toxicity, sodium bicarbonate for tricyclic antidepressants, and hypertonic dextrose for sulfonylurea-induced neuroglycopenia.
Toxic hyperthermia (core temperature > 40.0°C to 41.0°C) is a medical emergency requiring immediate active external cooling (evaporative mist with high-velocity fans) to prevent rhabdomyolysis, DIC, and multiorgan failure; standard antipyretics (acetaminophen, NSAIDs) are completely ineffective and potentially hepatotoxic/nephrotoxic.
If chemical neuromuscular paralysis is required for intractable toxic rigidity, seizures, or severe hyperthermia, non-depolarizing neuromuscular blockers (vecuronium, rocuronium) must be utilized; succinylcholine is strictly contraindicated due to lethal hyperkalemia from underlying rhabdomyolysis and malignant hyperthermia risk.
Toxic hemodynamic shock requires precise classification: distributive vasoplegic shock responds primarily to norepinephrine and alpha-1 vasopressors, whereas cardiogenic pump failure requires inotropes, HIET, and targeted antidotes, with early deployment of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) serving as a high-survival bridge to recovery.
Last updated: September 2026
While targeted antidotes and enhanced elimination are vital therapeutic pillars in clinical toxicology, the overwhelming majority of poisoned patients survive or succumb based entirely on the quality of advanced supportive care and resuscitation . In severe, life-threatening poisonings, toxicological disruption converges upon three critical physiological failure modes: toxic status epilepticus , malignant hyperthermia , and refractory hemodynamic shock . Mastering the specialized resuscitation principles that distinguish toxicological emergencies from standard medical critical care is paramount for the Specialist in Poison Information (CSPI).
Toxic Seizures and Status Epilepticus
Toxic-induced seizures account for approximately 10% of all status epilepticus presentations in emergency departments. Unlike idiopathic epilepsy, toxic seizures are triggered by acute biochemical disruptions of central neuronal equilibrium—predominantly loss of GABA-mediated inhibitory tone or excessive excitatory monoaminergic / sodium-channel depolarization . Neurochemical Classification of Toxic Seizures:
- 1. GABA Depletion / Synthesis Inhibition: Isoniazid (INH), Gyromitra mushrooms, Hydrazines
- 2. GABA-A Receptor Channel Antagonism: Cicutoxin (Water Hemlock), Organochlorines (Lindane), Picrotoxin
- 3. Sodium Channel & Monoamine Excitation: Tricyclic Antidepressants (TCAs), Bupropion, Tramadol, Cocaine
- 4. Glycine Receptor Antagonism: Strychnine (Spinal convulsions with preserved sensorium)
- 5. Cellular Hypoxia & Metabolic Depletion: Cyanide, Carbon Monoxide, Sulfonylurea-induced Hypoglycemia
- 1. Pharmacological Management Hierarchy
First-Line Therapy: Intravenous Benzodiazepines: Benzodiazepines are the undisputed first-line agents for all toxic seizures. They bind to the allosteric gamma subunit of the GABA_A receptor , increasing the open frequency of the chloride channel and enhancing endogenous GABA inhibitory neurotransmission.
Lorazepam: 0.1 mg/kg IV (typically 2 to 4 mg IV in adults) administered every 3 to 5 minutes.
Diazepam: 0.2 mg/kg IV (typically 5 to 10 mg IV in adults) every 3 to 5 minutes.
Midazolam: 0.2 mg/kg IM/IV (typically 5 to 10 mg in adults); excellent intramuscular absorption when IV access is not yet established.
Second-Line Therapy: Barbiturates and Propofol: If seizures persist despite high-dose benzodiazepines (e.g., > 12 to 16 mg of lorazepam):
Phenobarbital: 20 mg/kg IV infused at up to 50 mg/min. Unlike benzodiazepines, barbiturates increase the duration of chloride channel opening and, at higher concentrations, directly open GABA_A channels independently of endogenous GABA . This makes phenobarbital exceptionally effective when GABA stores are depleted.
Propofol: Rapid-acting GABA_A agonist and NMDA blocker; 1 to 2 mg/kg IV bolus followed by continuous infusion (20 to 100 mcg/kg/min).
2. The Critical Contraindication of Phenytoin
ABSOLUTE CLINICAL RULE: Phenytoin and fosphenytoin are completely ineffective in toxic-induced seizures and are STRICTLY CONTRAINDICATED in overdoses involving sodium-channel blocking xenobiotics (such as tricyclic antidepressants, diphenhydramine, and cocaine).
Mechanistic Ineffectiveness: Phenytoin acts selectively on voltage-gated neuronal sodium channels, prolonging the inactivated state to suppress high-frequency focal epileptic spikes. It exerts zero action on GABA receptors, glycine receptors, or metabolic cellular respiration. In toxic seizures driven by GABA depletion or monoaminergic storm, phenytoin has zero clinical efficacy in terminating seizures.
Lethal Cardiac Toxicity: In poisonings involving sodium channel blocking agents (TCAs, cocaine, propoxyphene, diphenhydramine), phenytoin produces additive, synergistic myocardial sodium channel blockade . Administering phenytoin in TCA overdose precipitates widening of the QRS complex, refractory ventricular tachycardia, complete AV block, and asystole.
3. Toxin-Specific Seizure Antidotes
When a specific toxin is responsible, targeted antidotes must be administered immediately alongside benzodiazepines:
Isoniazid (INH) and Gyromitra Mushrooms: Administer intravenous pyridoxine (vitamin B6) gram-for-gram matching the ingested dose (or 5 g IV push empiric). Replaces the coenzyme necessary for glutamic acid decarboxylase to synthesize GABA.
Tricyclic Antidepressants (TCAs): Administer sodium bicarbonate (1 to 2 mEq/kg IV push) to overcome myocardial sodium channel blockade, narrow the QRS, and raise serum pH.
Hypoglycemic Agents (Sulfonylureas, Insulin): Administer 50% dextrose (D50W, 50 mL IV) followed by octreotide for sulfonylureas.
Organophosphates / Nerve Agents: Administer atropine and pralidoxime (2-PAM) ; control status epilepticus with high-dose midazolam.
Toxic Hyperthermia and Severe Temperature Derangements
Toxic hyperthermia—defined as an elevation in core body temperature exceeding 40.0°C to 41.0°C (104.0°F to 105.8°F) —represents an acute, life-threatening toxicological emergency. At core temperatures exceeding 40.5°C, direct thermal cytotoxicity triggers protein denaturation, cell membrane liquefaction, endothelial injury, disseminated intravascular coagulation (DIC) , massive rhabdomyolysis, and multisystem organ failure. Core Toxic Hyperthermia Syndromes:
- Sympathomimetic Storm: Psychomotor agitation + Peripheral vasoconstriction (Cocaine, Methamphetamine)
- Serotonin Syndrome: Hunter Criteria (Spontaneous/inducible clonus, ocular clonus, tremor, diaphoresis)
- Neuroleptic Malignant: Dopamine D2 blockade ('Lead-pipe' rigidity, hyporeflexia, fever, slow onset)
- Malignant Hyperthermia: Ryanodine receptor defect (Triggered by volatile anesthetics / succinylcholine)
- Mitochondrial Uncouplers: Salicylates, 2,4-Dinitrophenol (DNP) (Massive ATP uncoupling; heat without rigidity)
- 1. Pathophysiological Differentiation of Hyperthermic Syndromes
Syndrome Primary Offending Agents Pathognomonic Neuromuscular Hallmarks Autonomic / Secretory Signs Specific Management
Sympathomimetic Excitation Cocaine, Methamphetamine, MDMA, Cathinones Tremors, hyperreflexia, severe psychomotor violent agitation Drenching diaphoresis , severe tachycardia, hypertension, mydriasis Aggressive IV benzodiazepines; evaporative cooling
Serotonin Syndrome (SS) SSRIs, SNRIs, MAOIs, Linezolid, Dextromethorphan Clonus (spontaneous, inducible, ocular) , hyperreflexia (lower > upper extremities) Profuse sweating, active bowel sounds, diarrhea, flushing Benzodiazepines; Cyproheptadine (12 mg PO load); active cooling
Neuroleptic Malignant Syndrome (NMS) Haloperidol, Fluphenazine, Atypical Antipsychotics 'Lead-pipe' generalized muscular rigidity , bradykinesia, stupor Sialorrhea, labile blood pressure, pallor, gradual onset (days) Bromocriptine, Amantadine; ICU supportive care
Malignant Hyperthermia (MH) Volatile anesthetics (halothane, isoflurane), Succinylcholine Hyperacute masseter spasm , generalized tetanic muscular rigidity Extreme hypercapnia (EtCO2 > 70), mottled cyanosis, rapid death Dantrolene (2.5 mg/kg IV push); 100% O2; active cooling
Mitochondrial Uncoupling 2,4-Dinitrophenol (DNP), Salicylates Tachypnea, diaphoresis; NO muscular rigidity (pure cellular heat) Extreme hyperpyrexia (> 42°C), rapid rigor mortis post-mortem Evaporative ice cooling; sodium bicarbonate; hemodialysis
2. Management Hierarchy: Cooling and Neuromuscular Paralysis Toxic Hyperthermia Resuscitation Flow:
- [Core Temperature > 40.0°C / 104°F Recorded via Indwelling Rectal/Bladder Probe]
- │
- ▼
- RAPID ACTIVE EXTERNAL COOLING (Evaporative mist + Continuous High-Velocity Fans)
- │
- ▼
- AGGRESSIVE SEDATION: IV Benzodiazepines (Diazepam 5-10 mg or Lorazepam 2-4 mg q5min)
- (Blunts central agitation, suppresses shivering, terminates seizures)
- │
- ▼
IF RIGIDITY, STATUS EPILEPTICUS, OR TEMP > 40.5°C PERSISTS:
- Elective Rapid Sequence Intubation + NON-DEPOLARIZING Neuromuscular Blockade
- (Vecuronium 0.1 mg/kg or Rocuronium 1.0 mg/kg IV)
- │
- ▼
- TARGET ENDPOINT: Core Temperature Dropped to < 38.5°C (101.3°F) Within 30-45 Minutes
Evaporative Cooling: The single most efficient, rapid, and non-invasive method of heat dissipation. The patient is stripped naked, sprayed continuously with lukewarm water mist , and exposed to high-velocity circulating fans . Lukewarm water prevents peripheral cutaneous vasoconstriction and shivering, maximizing radiant and evaporative heat loss. Ice packs applied to the axillae and groin provide supplemental conductive cooling.
THE ABSOLUTE BAN ON ANTIPYRETICS: Antipyretic medications—specifically acetaminophen and NSAIDs (ibuprofen, ketorolac) —are COMPLETELY INEFFECTIVE in toxic hyperthermia. Infectious fevers elevate the hypothalamic set-point via pyrogenic cytokines (IL-1, PGE2). Toxic hyperthermia results from unbridled peripheral muscular thermogenesis, cellular mitochondrial uncoupling, or impaired heat dissipation. Antipyretics do not alter peripheral heat generation and introduce severe hepatotoxicity and nephrotoxicity.
Chemical Neuromuscular Blockade: When skeletal muscle hyperactivity or severe rigidity drives hyperpyrexia refractory to benzodiazepines, the patient must be paralyzed. Paralyzing skeletal muscle eliminates the motor endplate mechanical work that produces internal heat.
THE SUCCINYLCHOLINE CONTRAINDICATION: Always use non-depolarizing neuromuscular blockers (rocuronium or vecuronium). Depolarizing neuromuscular blockade with succinylcholine is strictly contraindicated ; it provokes massive sarcoplasmic potassium release in patients with underlying rhabdomyolysis (triggering fatal hyperkalemic cardiac arrest) and can trigger malignant hyperthermia.
Toxic Hemodynamic Shock and Extracorporeal Support
Toxicological shock is categorized hemodynamically into distributive (vasoplegic) shock and cardiogenic shock . Hemodynamic Shock Differentiation:
- Distributive Shock (Vasoplegia): Low SVR + Warm Peripheries + Normal/High Initial Cardiac Output
- Etiologies: Phenothiazines, Atypical Antipsychotics, Trazodone, Dihydropyridine CCBs, Sepsis-mimics
- Resuscitation: Balanced Crystalloids (1-2 L) ──► Norepinephrine (First-Line) ──► Vasopressin
- Cardiogenic Shock (Pump Failure): Low Cardiac Output + Elevated SVR/CVP + Cold Peripheries + Pulmonary Edema
- Etiologies: Beta-Blockers, Non-Dihydropyridine CCBs (Verapamil, Diltiazem), TCAs, Digoxin, Flecainide
- Resuscitation: Inotropes (Epinephrine) ──► HIET / Calcium / Glucagon ──► VA-ECMO Deployment
- 1. Distributive Vasoplegic Shock
Mechanisms: Antagonism of peripheral vascular alpha-1 adrenergic receptors (phenothiazines, trazodone, quetiapine), profound inhibition of vascular L-type calcium channels (amlodipine, nicardipine), or severe metabolic acidemia.
Resuscitation Strategy:
Administer 1 to 2 liters of balanced isotonic crystalloid (Plasmalyte or Lactated Ringer's). Avoid fluid overload.
If mean arterial pressure remains < 65 mmHg, initiate norepinephrine as the first-line vasopressor. Norepinephrine provides potent alpha-1 vasoconstriction to restore systemic vascular resistance combined with modest beta-1 inotropic support.
If vasoplegia is refractory, add vasopressin (0.03 to 0.04 units/min) as a second-line non-adrenergic vasoconstrictor (acts via vascular V₁ receptors).
2. Cardiogenic Toxic Shock
Mechanisms: Direct myocardial depression, sinus arrest, advanced atrioventricular nodal blockade, or impaired sarcoplasmic calcium release resulting from beta-blockers, verapamil, diltiazem, or sodium channel blockers.
Resuscitation Strategy: Fluid boluses must be administered with extreme caution to avoid precipitating pulmonary edema. Vasopressors with pure alpha activity (such as phenylephrine) are contraindicated because they augment cardiac afterload without improving contractility.
Epinephrine: The preferred adrenergic vasoactive infusion for cardiogenic shock. Provides potent beta-1 chronotropy and inotropy combined with alpha-1 vascular tone.
High-Dose Insulin Euglycemia Therapy (HIET): Initiated early (1 unit/kg bolus + 1 to 10 units/kg/hr infusion) to restore myocardial carbohydrate metabolism.
Targeted Inotropes: Dobutamine or milrinone may be cautiously added only if systemic vascular resistance is adequate.
3. Mechanical Circulatory Support: Veno-Arterial ECMO
When toxic cardiogenic shock or malignant ventricular dysrhythmias prove refractory to maximum pharmacological resuscitation, Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) represents the definitive life-saving salvage therapy.
Core Mechanism: Blood is drained from the right atrium via a large venous cannula, pumped through an external membrane oxygenator, and returned under high arterial pressure into the femoral or carotid artery, completely bypassing the non-functioning heart and lungs.
The 'Bridge to Recovery / Elimination' Concept: In medical critical care, cardiogenic shock secondary to acute myocardial infarction carries a high mortality because the myocardium is irreversibly infarcted. In toxicology, the myocardium is merely biochemically poisoned, not dead . If VA-ECMO maintains systemic end-organ perfusion for 24 to 72 hours, the liver and kidneys will clear the offending xenobiotic, allowing the stunned myocardium to make a full, complete functional recovery.
Clinical Indications for Toxicological ECMO: Refractory cardiogenic shock (cardiac index < 1.8 L/min/m², arterial lactate > 8 to 10 mmol/L despite triple vasopressors/inotropes), recurrent refractory ventricular fibrillation / tachycardia, or toxic cardiac arrest (Extracorporeal Cardiopulmonary Resuscitation - ECPR).
Resuscitation and Hemodynamic Support Matrix
Clinical Failure Mode Offending Toxicological Classes First-Line Resuscitation Protocol Secondary Escalation Interventions Lethal Pitfalls & Contraindicated Therapies
Toxic Status Epilepticus INH, Cicutoxin, TCAs, Bupropion, Cocaine, Organochlorines IV Benzodiazepines (Lorazepam 0.1 mg/kg or Midazolam 0.2 mg/kg IV/IM) Phenobarbital (20 mg/kg IV); Propofol infusion; Pyridoxine (for INH) Phenytoin is strictly contraindicated (ineffective; additive cardiotoxicity in sodium channel blocker ingestions)
Toxic Hyperthermia (> 40°C) Sympathomimetics, Serotonin Syndrome, NMS, Salicylates Rapid active evaporative cooling (lukewarm mist + circulating fans) IV Benzodiazepines; Non-depolarizing paralysis (Rocuronium); Cyproheptadine (for SS) Antipyretics (APAP/NSAIDs) are ineffective ; Succinylcholine is contraindicated (hyperkalemic arrest / MH)
Distributive Vasoplegic Shock Phenothiazines, Quetiapine, Trazodone, Amlodipine Isotonic crystalloid bolus (1–2 L) + Norepinephrine infusion Vasopressin (0.03 u/min); Angiotensin II; Methylene blue (for refractory vasoplegia) Excessive crystalloid administration without early vasopressors induces pulmonary edema
Cardiogenic Toxic Shock CCBs (Verapamil, Diltiazem), Beta-blockers, TCAs, Digoxin Epinephrine infusion + High-Dose Insulin (HIET) + IV Calcium Glucagon (3–10 mg IV); 20% Lipid Emulsion; VA-ECMO deployment Phenylephrine contraindicated (increases afterload on failing heart); avoid fluid overload
Poison Center Case Scenario: Refractory Bupropion Overdose with Status Epilepticus and Shock
A 22-year-old college student is found unresponsive by roommates surrounded by two empty bottles of extended-release bupropion (bupropion XL 300 mg, total ingested dose: approximately 18 g). On EMS arrival, the patient is in active generalized tonic-clonic status epilepticus. EMS administers 10 mg of intramuscular midazolam with only partial cessation of motor seizure activity. On arrival in the resuscitation bay, vital signs are: heart rate 158 beats/min, blood pressure 72/40 mmHg, respiratory rate 26 breaths/min (intubated), and core rectal temperature 40.8°C (105.4°F). Continuous 12-lead ECG reveals an extreme intraventricular conduction defect with a QRS duration of 172 ms and terminal R wave in aVR.
Specialist in Poison Information Interventions
Refractory Status Epilepticus Control: The CSPI cautions that bupropion (a norepinephrine-dopamine reuptake inhibitor) is strongly proconvulsant in overdose and that seizures can recur for many hours with extended-release tablets. The CSPI instructs the emergency team to immediately escalate anticonvulsant therapy with lorazepam 4 mg IV , administer a loading dose of phenobarbital (20 mg/kg IV) , and initiate a continuous propofol infusion . The physician is explicitly warned never to administer phenytoin .
Immediate Hyperthermia Management: Because core temperature exceeds 40.5°C, immediate active cooling is initiated with continuous evaporative lukewarm water mist and high-velocity fans , combined with ice packs applied to the axillae and groin. Antipyretics are prohibited. Neuromuscular paralysis with rocuronium (1.0 mg/kg IV) is maintained to eliminate skeletal muscle thermogenesis, and continuous EEG monitoring is requested because paralysis hides ongoing seizure activity. Core temperature drops to 38.2°C within 35 minutes.
Cardiovascular Collapse and QRS Widening: Bupropion metabolites directly inhibit cardiac voltage-gated sodium channels and gap junction intercellular communication. The CSPI directs:
Boluses of hypertonic sodium bicarbonate (100 mEq IV push) repeated to narrow the QRS complex below 120 ms and maintain blood pH between 7.50 and 7.55.
Initiation of norepinephrine and epinephrine infusions to restore perfusion pressure.
Emergent Mechanical Circulatory Support (VA-ECMO): Two hours into resuscitation, the patient develops refractory cardiogenic shock with an arterial lactate of 14 mmol/L and recurrent bursts of polymorphic ventricular tachycardia. Following the CSPI's guidance, the regional Extracorporeal Life Support team cannulates the femoral vessels and initiates Veno-Arterial ECMO . With organ perfusion secured, bupropion and its active hydroxybupropion metabolites are cleared over 48 hours. The patient is successfully decannulated on hospital day 3 with intact neurological function and discharged home on day 8.